Back

PARP1 mediates the PI3K/AKT signaling pathway through PARylation-dependent to alleviate the myocardial injury caused by Cediranib

31 August 2026 (13:15 - 13:35)
Organised by: Logo
Congress Presentation Part of: Cardiac remodelling, fibrosis, and heart failure Drugs, Drug Targets ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Xin Ma

Lanzhou (China)

2 More presentations in this session

Presentation thumbnail
The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme
Doctor J. Jensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Itaconate reduces mitochondrial respiratory threshold and improves both inotropy and lusitropy in human hypertrophic myocardium
Doctor Y. Ng (Sydney, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac remodelling, fibrosis, and heart failure

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular toxicities reported with Poly ADP Ribose Polymerase (PARP) inhibitors in the FDA Adverse Event Reporting System
21 June 2025
thumbnail
Congress Presentation
Role of PI3K/Akt and MEK/ERK signalling in Epac-mediated endothelial barrier stabilisation and survival
22 April 2018
thumbnail
Congress Presentation
Relevance of necroptosis in the hearts subjected to acute versus chronic ischemia/reperfusion injury
29 April 2022
thumbnail
Congress Presentation
The role of acetyltransferase PCAF in cardiac remodeling
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources